Abstract
Purpose: Osteoarthritis (OA) is characterized by the loss of the articular cartilage, bone remodelling, pain, and disability. It is a leading cause of disability in older people. At current, there are no disease modifying OA drugs to stop progression. Several potential targets to treat OA have been identified, including from our lab: ROR2, Agrin and WNT16. One bottleneck in clinical translation is that the cartilage extracellular matrix is avascular and largely impenetrable for large macromolecules including antibodies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
